We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
101
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.23M 0.01%
106,616
-11,484
-10% -$251K
CHMA
102
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.23M 0.01%
742,133
– –
AKRO
103
DELISTED
Akero Therapeutics
AKRO
$3.05M 0.01%
118,378
-13,410
-10% -$373K
XLRN
104
DELISTED
Acceleron Pharma
XLRN
$2.87M 0.01%
22,430
-3,210
-13% -$376K
DRNA
105
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$2.25M 0.01%
102,121
-11,014
-10% -$243K
INZY
106
DELISTED
Inozyme Pharma
INZY
$2.21M 0.01%
106,999
-11,501
-10% -$274K
OVID icon
107
Ovid Therapeutics
OVID
$427M
$2.21M 0.01%
955,690
+364,929
+62% +$1.7M
VKTX icon
108
Viking Therapeutics
VKTX
$3.88B
$2.05M 0.01%
363,980
-40,220
-10% -$244K
RCUS icon
109
Arcus Biosciences
RCUS
$3.33B
$1.89M 0.01%
72,709
-42,716
-37% -$1.03M
ORTX
110
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.44M 0.01%
33,250
-1,070
-3% -$47.9K
CYPH
111
Cypherpunk Technologies Inc
CYPH
$64M
$1.26M ﹤0.01%
55,971
– –
MTEM
112
DELISTED
Molecular Templates, Inc.
MTEM
$1.26M ﹤0.01%
8,922
-999
-10% -$148K
OYST
113
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.16M ﹤0.01%
61,424
-6,804
-10% -$147K
LKFT
114
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$1.11M ﹤0.01%
11,180
-1,232
-10% -$151K
INFI
115
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.11M ﹤0.01%
522,360
-58,040
-10% -$95.7K
EVFM
116
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$991K ﹤0.01%
27,426
-1,444
-5% -$52.2K
AFMD
117
DELISTED
Affimed
AFMD
$958K ﹤0.01%
16,461
-2,519
-13% -$119K
BLCM
118
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$879K ﹤0.01%
249,123
– –
KZR
119
DELISTED
Kezar Life Sciences
KZR
$729K ﹤0.01%
13,968
-43,528
-76% -$2.42M
ADMS
120
DELISTED
Adamas Pharmaceuticals
ADMS
$641K ﹤0.01%
147,996
-15,834
-10% -$67.8K
GLMD icon
121
Galmed Pharmaceuticals
GLMD
$4.62M
$575K ﹤0.01%
1,027
-114
-10% -$71.2K
QURE icon
122
uniQure
QURE
$2.75B
$244K ﹤0.01%
6,740
-187,643
-97% -$7.92M
VIRX
123
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$106K ﹤0.01%
15,162
– –
GNFT
124
DELISTED
Genfit
GNFT
$71K ﹤0.01%
14,720
-13,676
-48% -$64.3K
APLT
125
DELISTED
Applied Therapeutics
APLT
– –
-38,034
Closed -$790K
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.